Analyst Price Target is $1.50
▲ +114.29% Upside Potential
This price target is based on 0 analysts offering 12 month price targets for Trevena in the last 3 months. The average price target is $1.50, with a high forecast of $1.50 and a low forecast of $1.50. The average price target represents a 114.29% upside from the last price of $0.70.
Current Consensus is
The current consensus among 0 investment analysts is to n/a stock in Trevena. This rating has held steady since October 2022, when it changed from a Hold consensus rating.
Trevena, Inc. engages in the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.